The Bridge has a stated window
The Bridge’s recorded end date is December 31, 2027; its opening date was July 1, 2026. CMS, the agency running Medicare, specified a monthly $50 share of the cost for those who qualify; these terms were checked September 26, 2026.
A copay is the person’s share for a supply through that arrangement. The drug benefit within Medicare goes by Part D. The Bridge is a temporary test program that tries a different way of paying for medicine, outside Part D’s usual payment system.
Ask the prescriber to identify the program by name when discussing it. A vague reference to a Medicare price can hide the distinction between ordinary plan payment and this temporary route. Keep the answer with the exact medicine and form being considered.
Eligibility needs a separate review
The September 26, 2026 rules require an age of at least 18. They use body mass index (BMI), a weight measure based on height, when this treatment began.
A value of 35 or higher for BMI meets the weight criterion without any other condition from the program’s list. A different path uses BMI 30 or higher plus a specified heart-failure condition, uncontrolled blood pressure, or kidney disease stage 3a and above. The blood-pressure criterion is a top reading over 140 or a bottom reading over 90 while taking two medicines for blood pressure. The relevant heart diagnosis goes by “heart failure with preserved ejection fraction.”
Another path combines BMI 27 or higher with a previous stroke, previous heart attack, prediabetes, or symptomatic peripheral artery disease. Peripheral artery disease with symptoms means problems from narrowed arteries in the limbs.
The required coverage is either a stand-alone Part D plan or coordinated-care Medicare Advantage with drug coverage. A prescription and the program’s permission before the fill are required, along with ongoing structured changes to eating and physical activity.
The prior-use rule concerns the group of drugs called GLP-1 medicines. During 2026, any earlier GLP-1 payment through Part D blocks Bridge eligibility for that year. The September 26, 2026 rules had not yet set how prior use would affect eligibility in 2027.
A diagnosis of type 2 diabetes routes the person away from the Bridge toward ordinary Part D consideration under those September 26, 2026 terms.
Those terms also exclude moderate or severe obstructive sleep apnea and noncirrhotic MASH with moderate or advanced liver scarring. MASH names a specific fatty liver disease; noncirrhotic means cirrhosis is not present. Part D also reviews a prescription whose purpose is lowering the risk of major cardiovascular events, such as heart attacks or strokes.
Have the prescriber review the current program criteria against the actual record. Note anything that still needs to be checked. Ask what information is missing and who will submit it. If another condition changes the route, ask for that to be put in plain words.
The program’s own eligibility page is the place to read the full criteria. A short advertisement cannot stand in for that review.
Where the copay counts
Under the September 26, 2026 terms, the $50 is kept separate from the money counted toward Part D’s yearly spending limit. The Bridge offers no extra help to lower that payment for people with low incomes, so they still owe the full $50 monthly share.
CMS also bars coupons on Bridge claims, and the copay cannot use the Medicare Prescription Payment Plan to spread a fill across months, as checked September 26, 2026.
Ask what that means for the rest of your prescription spending. Keep the Bridge amount on its own line when reviewing a budget. Do not assume that money paid through this route has the same effect on plan spending as another prescription charge.
If a payment estimate includes a coupon or a different financing arrangement, ask the person providing it to reconcile the estimate with the Bridge rules.
The product form matters too
The product list checked September 26, 2026 includes semaglutide (Wegovy) as injection and tablets, orforglipron (Foundayo), and tirzepatide (Zepbound) only in the KwikPen injection device.
The product’s form identifies how it comes: as a tablet or injection, with the particular device used to supply it. A familiar brand name does not mean every form or device is included. Ask the prescriber and pharmacy to confirm the exact form against the program list.
Ask how a change in the proposed prescription would be reviewed. Keep the program’s dated answer, rather than treating a past approval as a general promise about another medicine. The source notes link back to the official pages for the program and its limits.